BSX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Boston Scientific Corp (BSX) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. Despite recent challenges, the company's strong financial performance, positive congressional trading activity, and growth opportunities in the medical device sector outweigh the short-term headwinds.
The technical indicators show mixed signals. The MACD is positive but contracting, RSI is neutral at 36.314, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its support level (S1: 71.717), suggesting limited downside risk. However, it has yet to break above key resistance levels (Pivot: 74.055).
Strong Q4 financial performance with revenue up 15.90% YoY and net income up 18.94% YoY.
Congressional trading activity shows heavy buying, indicating confidence in the stock.
Growth opportunities in the aging population and medical device sector.
Expansion of product lines and strategic acquisitions like Penumbra.
Insider selling has increased significantly (755.62% over the last month).
Class action lawsuits and investigations for securities fraud may create short-term headwinds.
Analysts have lowered price targets due to disappointing Q4 U.S. EP sales and conservative guidance.
Bearish sentiment in the options market and technical indicators.
In Q4 2025, Boston Scientific reported strong financials: Revenue increased by 15.90% YoY to $5.29B, net income rose by 18.94% YoY to $672M, and EPS grew by 18.42% YoY to $0.45. Gross margin also improved to 65.38%, up 3.76% YoY, indicating robust profitability.
Analysts maintain a generally positive outlook with multiple Buy and Outperform ratings, despite lowering price targets due to short-term challenges. The average price target remains significantly above the current price, reflecting long-term growth potential.
